Enalaprilat: Difference between revisions
ClaireLewis (talk | contribs) (Created page with "==Administration== *Type: ACE inhibitor *Dosage Forms: *Routes of Administration: IV *Common Trade Names: Vasotec ==Adult Dosing== *1.25-5mg IV q6h *0.625 mg IV initially...") |
Elcatracho (talk | contribs) |
||
| (4 intermediate revisions by 3 users not shown) | |||
| Line 7: | Line 7: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*1.25-5mg IV q6h | *1.25-5mg IV q6h | ||
*0. | *0.625mg IV initially, with repeated dose of 0.625mg if inadequate response for the following patients: | ||
**CrCl <30 | **CrCl <30 | ||
**Severe volume or salt depletion, recent HD, or concomitant diuretic use | **Severe volume or salt depletion, recent HD, or concomitant diuretic use | ||
**CHF | **[[CHF]] | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
''Safety/efficacy not established'' | ''Safety/efficacy not established'' | ||
| Line 29: | Line 29: | ||
*Angioedema | *Angioedema | ||
===Common=== | ===Common=== | ||
*Hyperkalemia | *[[Hyperkalemia]] | ||
*Nausea | *Nausea | ||
*Headache | *Headache | ||
| Line 42: | Line 42: | ||
==See Also== | ==See Also== | ||
*[[Hypertension]] | |||
*[[ACE inhibitor]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Cardiology]] | |||
Latest revision as of 16:00, 8 March 2021
Administration
- Type: ACE inhibitor
- Dosage Forms:
- Routes of Administration: IV
- Common Trade Names: Vasotec
Adult Dosing
- 1.25-5mg IV q6h
- 0.625mg IV initially, with repeated dose of 0.625mg if inadequate response for the following patients:
- CrCl <30
- Severe volume or salt depletion, recent HD, or concomitant diuretic use
- CHF
Pediatric Dosing
Safety/efficacy not established
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk minimal
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
- Angioedema history (ACEi-induced, hereditary, or idiopathic)
Adverse Reactions
Serious
- Myocardial infarction
- Liver failure
- Angioedema
Common
- Hyperkalemia
- Nausea
- Headache
Pharmacology
- Half-life: ~11h
- Metabolism:
- Excretion: Renal. Dialyzable
Mechanism of Action
- Inhibits angiotensin converting enzyme, blocking conversion of angiotensin I to angiotensin II.